Aligos Therapeutics, Inc. ALGS
We take great care to ensure that the data presented and summarized in this overview for Aligos Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ALGS
Top Purchases
Top Sells
About ALGS
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Insider Transactions at ALGS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 25
2023
|
Lawrence Blatt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
610,277
+24.83%
|
$0
$0.76 P/Share
|
|
Oct 25
2023
|
Carole Nuechterlein |
BUY
Open market or private purchase
|
Indirect |
7,933,601
+41.84%
|
$0
$0.76 P/Share
|
|
Oct 25
2023
|
James Paul Scopa |
BUY
Grant, award, or other acquisition
|
Direct |
183,083
+50.0%
|
$0
$0.76 P/Share
|
|
Jun 11
2021
|
Thomas Woiwode Director |
BUY
Other acquisition or disposition
|
Direct |
2,226
+33.33%
|
-
|
|
Jun 11
2021
|
Thomas Woiwode Director |
SELL
Other acquisition or disposition
|
Indirect |
504,081
-75.0%
|
-
|
|
Jun 11
2021
|
Thomas Woiwode Director |
BUY
Other acquisition or disposition
|
Indirect |
18,102
+50.0%
|
-
|
|
Apr 26
2021
|
Thomas Woiwode Director |
BUY
Other acquisition or disposition
|
Direct |
2,226
+50.0%
|
-
|
|
Apr 26
2021
|
Thomas Woiwode Director |
SELL
Other acquisition or disposition
|
Indirect |
504,084
-73.33%
|
-
|
|
Apr 26
2021
|
Thomas Woiwode Director |
BUY
Other acquisition or disposition
|
Indirect |
18,105
+50.0%
|
-
|
|
Oct 20
2020
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,906,191
+36.53%
|
-
|
|
Oct 20
2020
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
200,000
+7.11%
|
$3,000,000
$15.0 P/Share
|
|
Oct 20
2020
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,414,563
+50.0%
|
-
|
|
Oct 20
2020
|
Leonid Beigelman President |
BUY
Conversion of derivative security
|
Indirect |
273,057
+25.02%
|
-
|
|
Oct 20
2020
|
Lawrence Blatt Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
273,058
+29.94%
|
-
|
|
Oct 20
2020
|
Carole Nuechterlein |
BUY
Conversion of derivative security
|
Indirect |
3,092,340
+25.83%
|
-
|
|
Oct 20
2020
|
Lucinda Y. Quan |
BUY
Conversion of derivative security
|
Indirect |
9,258
+24.62%
|
-
|
|
Oct 20
2020
|
Julian A. Symons |
BUY
Conversion of derivative security
|
Direct |
18,517
+1.54%
|
-
|
|
Oct 20
2020
|
Versant Venture Capital Vi, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
200,000
+18.82%
|
$3,000,000
$15.0 P/Share
|
|
Oct 20
2020
|
Versant Venture Capital Vi, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
662,444
+36.53%
|
-
|
|
Oct 20
2020
|
Versant Venture Capital Vi, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,429,895
+20.4%
|
-
|